Literature DB >> 21528219

Health-related quality of life during post-induction chemotherapy in children with acute lymphoblastic leukemia in remission.

R Barr1, C Petrie, W Furlong, M Rothney, D Feeny.   

Abstract

Using a multi-attribute approach, we and others have reported on the comprehensive health status of survivors of cancer in childhood, after completion of therapy. However, there is a dearth of information about health status and associated health-related quality of life (HRQL) in children and adults with cancer, during the treatment process; a deficit which this study was intended to redress. All children (n=18) receiving 'maintenance' chemotherapy for acute lymphoblastic leukemia (ALL) at a single institution were assessed prospectively through a single cycle of therapy. Patients, family members and health care professionals used global ratings, the health utilities index mark 2 (HUI2) and mark 3 (HUI3) classification systems, and detailed descriptions of temporary states of health, to provide independent assessments of health status at weekly intervals. Utility scores were derived for each comprehensive health state and for single attribute levels of the HUI2 system, and for the temporary health state descriptions. The classification of the subjects into the most appropriate temporary health states was challenging even for older children and some of the parents. The HUI instruments were used much more easily and produced highly comparable information. The most frequently affected attributes were pain, emotion and mobility/ambulation; in that order. The global (p=0.005) and specific morbidity burdens were, as predicted, greatest in the middle of the cycle of chemotherapy, reflecting the toxicity of steroid use. HUI2 global utility scores demonstrated moderate responsiveness with an intra-class correlation coefficient of 0.43. Cyclical administration of therapy, in particular corticosteroids, produces important changes in health status and HRQL in children with ALL. The HUI are valid and responsive systems for quantifying the burden of morbidity during the treatment of cancer in childhood. These are sensitive tools which can be used in a wide array of other circumstances to quantify changes in health status.

Entities:  

Year:  1997        PMID: 21528219     DOI: 10.3892/ijo.11.2.333

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

Review 1.  A comparative review of generic quality-of-life instruments.

Authors:  S J Coons; S Rao; D L Keininger; R D Hays
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

2.  Commentary on Cox CL, Lensing S, Rai SN et al. Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3. Qual Life Res 2005; 14: 1045-1056.

Authors:  William Furlong; Ronald D Barr
Journal:  Qual Life Res       Date:  2006-08-26       Impact factor: 4.147

3.  Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Authors:  Helen Dakin; Stavros Petrou; Mark Haggard; Sarah Benge; Ian Williamson
Journal:  Qual Life Res       Date:  2009-11-26       Impact factor: 4.147

4.  Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3.

Authors:  Cheryl L Cox; Shelly Lensing; Shesh N Rai; Pam Hinds; Elizabeth Burghen; Ching-Hon Pui
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

5.  Inter-observer agreement of a comprehensive health status classification system for pre-school children among patients with Wilms' tumor or advanced neuroblastoma.

Authors:  P C Nathan; W Furlong; J Horsman; C Van Schaik; M Rolland; S Weitzman; D Feeny; R D Barr
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

6.  Health-related quality of life among children with acute lymphoblastic leukemia.

Authors:  William Furlong; Charlene Rae; David Feeny; Richard D Gelber; Caroline Laverdiere; Bruno Michon; Lewis Silverman; Stephen Sallan; Ronald Barr
Journal:  Pediatr Blood Cancer       Date:  2012-01-31       Impact factor: 3.167

Review 7.  Measuring quality of life in paediatric patients.

Authors:  M A Connolly; J A Johnson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 8.  Quality of life in clinical trials for children.

Authors:  Annalisa Trama; Massimiliano Dieci
Journal:  Eur J Clin Pharmacol       Date:  2010-11-21       Impact factor: 2.953

9.  Construct validation of the Health Utilities Index and the Child Health Questionnaire in children undergoing cancer chemotherapy.

Authors:  L Sung; M L Greenberg; J J Doyle; N L Young; S Ingber; J Rubenstein; J Wong; T Samanta; M McLimont; B M Feldman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia.

Authors:  Raphaële R L van Litsenburg; Jaap Huisman; Rob Pieters; Chris Verhaak; Gertjan J L Kaspers; Reinoud J B J Gemke
Journal:  Support Care Cancer       Date:  2014-07-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.